Canadian Medical Association Journal Home |
Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema
The steering committee is part of Health Canada's Canadian Breast Cancer Initiative. A list of committee members appears in Appendix 1. A patient version of these guidelines appears in Appendix 2.
Abstract
Objective: To provide information and recommendations for women and their physicians when making decisions about the management of lymphedema related to breast cancer.
Options: Compression garments, pneumatic compression pumps, massage and physical therapies, other physical therapy modalities, pharmaceutical treatments.
Outcomes: Symptom control, quality of life, cosmetic results.
Evidence: Systematic review of English-language literature retrieved primarily from MEDLINE (1966 to April 2000) and CANCERLIT (1985 to April 2000). Nonsystematic review of breast cancer literature published to October 2000.
Recommendations:
Validation: An initial draft of this document was developed by a task force sponsored by the BC Cancer Agency. It was updated and revised substantially by a writing committee and then submitted for further review, revision and approval by the Steering Committee for Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
Sponsor: The steering committee was convened by Health Canada.
Completion date: October 2000. Lymphedema in women treated for breast cancer is an accumulation of protein-rich fluid in the arm that occurs when axillary lymphatic drainage from the arm is interrupted because of axillary lymph node dissection or axillary radiation, or both. Lymphedema remains a problem even with modern treatment modalities. Affected women can experience pain, swelling of the arm, tightness and heaviness in the arm and recurrent skin infections. Three stages of lymphedema have been described.1,2,3 Stage I presents with pitting and is considered reversible; some women with this stage have no increased arm girth or heaviness and no signs of pitting edema. As the edema progresses, it becomes brawny, fibrotic, nonpitting and irreversible (stage II). In advanced lymphedema (stage III), which rarely occurs following breast cancer treatments, cartilaginous hardening occurs, with papillomatous outgrowths and hyperkeratosis of the skin. In this guideline, we provide an evidence-based approach to the management of this difficult problem. Methods
This guideline document is based on a systematic review of English-language literature retrieved from MEDLINE (1966 to April 2000) and CANCERLIT (1985 to April 2000). Medical subject headings used were "breast," "breast neoplasms," "lymph node excision," "mastectomy" and "lymphedema." Randomized controlled trials comparing different modalities would provide the strongest evidence for recommending best treatments for lymphedema. However, given the lack of data from such studies, a broader strategy without limits set by methodological search criteria was used. Review articles and textbook chapters were also consulted, primarily to provide background information and to secure additional references. A nonsystematic review of the breast cancer literature to October 2000 also took place. Rules of evidence as described by Sackett4 were used for grading the levels of experimental studies.
An initial draft of this guideline document was developed by a task force sponsored by the BC Cancer Agency that was convened in March 1997. The task force comprised physical therapists, breast surgeons, radiation and medical oncologists, and breast cancer patients living with lymphedema. The draft was reviewed by clinical practitioners and by representatives of the British Columbia College of Physicians and Surgeons, the Registered Nurses' Association of British Columbia, the College of Physical Therapists of British Columbia and the British Columbia Council on Clinical Practice Guidelines. The Breast Tumour Group at the BC Cancer Agency then approved the guideline in October 1997. The initial draft was updated and revised substantially by a writing committee and then submitted for further review, revision and approval by the Steering Committee for Clinical Practice Guidelines for the Care and Treatment of Breast Cancer, sponsored by Health Canada. Recommendations (including evidence and rationale) Measurement
There is no consistent operational definition of "clinically significant lymphedema" in the literature. The lack of a consistent definition leads to confusion regarding the incidence of lymphedema after breast cancer treatment. The following criteria have been used in the literature to measure lymphedema: absolute increase in volume or percentage increase in volume as determined by water displacement, circumferential measurements and patient symptoms.5,6 Results of studies comparing differences in arm circumferences with volume differences are conflicting.7,8 In a recent study Megens8 reported that both circumferential measurements and water displacement volumetry in women with breast cancer had excellent interrater and testretest reliability, although the 2 methods had poor agreement with each other.
Circumferential measurements are widely used because tape measures are readily available and because volumetric measurement is logistically difficult. One common approach involves measuring the circumferences of both arms at points 13 to15 cm proximal and 10 cm distal to the lateral epicondyle of the humerus.9 Differences greater than 2.0 cm at any point are defined by some as "clinically significant,"5,10 whereas others classify this degree of lymphedema as mild.11,12 Other methods for assessing lymphedema, including lymphoscintigraphy, MRI, CT scanning and ultrasound, are being evaluated in research settings.13
Incidence of lymphedema
Given the variation of criteria used to define lymphedema and the variety of assessment techniques, it is not surprising to see wide variation in the reported incidence of lymphedema following breast cancer treatment. Lymphedema rates of 6% to 70% among patients with breast cancer have been reported.5,14,15,16,17,18 Petrek and Heelan19 reported on the incidence of lymphedema after breast cancer treatment in a review of 7 studies published since 1990. These studies were all retrospective, differed in patient populations, used different criteria to measure lymphedema and had varying degrees of follow-up. The incidence of lymphedema ranged from 2% to 24%.
Transient lymphedema occurs in a number of patients following axillary dissection. In a study involving 282 women who underwent breast-conserving surgery including axillary dissection, Werner and colleagues10 reported that transient edema occurred in 21 (7%) of the women and persistent edema in 24 (12%). The median time to development of persistent edema was 14 months (range 292 months).
Irradiation of the axilla increases the risk of lymphedema. In a randomized controlled trial conducted in British Columbia, chemotherapy alone was compared with chemotherapy plus regional radiation therapy in women with node-positive breast cancer after modified radical mastectomy.20 The reported rate of lymphedema was 9.1% among the irradiated subjects and 3.2% among those who received chemotherapy alone. Although the risk of lymphedema increases with irradiation of the axilla, this risk is also influenced by the extent of axillary dissection.21,22,23,24 Other factors that have been implicated in the development of lymphedema are obesity,10 extensive axillary disease22 and recurrent cancer in the axillary lymph nodes.25
Chronic and severe lymphedema may very rarely give rise to lymphangiosarcoma. The incidence of this complication is rarely reported among lymphedema patients; in unselected patients the risk is less than 1%.25 In a population-based Swedish study involving 122 991 women treated for breast cancer between 1958 and 1992, angiosarcoma developed in only 35 women.26 However, 26 (74%) of the 35 women had lymphedema. Management Before any type of lymphedema treatment is started, tumour involvement of the axilla or brachial plexus, infection and axillary vein thrombosis should be looked for and treated if present. The systematic review of literature on the management of lymphedema was limited by the lack of prospective randomized trials evaluating different treatment options. Compression garments
Graded compression garments that deliver pressures of 20 to 60 mm Hg are the mainstay of lymphedema therapy and can be used as primary therapy.1,27,28 Some clinicians recommend the use of a compression garment for up to 24 hours per day, while others recommend its use only during waking hours or exercise.9,12,29,30,31,32 Compression garments may also protect the extremity from injuries such as burns, lacerations and insect bites.
Collins and colleagues33 used CT scanning to assess the effect of compression garment therapy in 27 women with unilateral lymphedema. They found significant decreases in the cross-sectional area of subcutaneous compartments: the mean decrease was 9% in the proximal portion and 26% in the distal portion of the limb (level V evidence).
In one of the few randomized controlled trials of lymphedema, the use of a compression sleeve plus electrically stimulated lymphatic drainage was compared with the use of a compression sleeve alone.9 Both modalities reduced limb girth by 17%, which suggested that compression sleeve therapy alone is effective (level II evidence).
Good compression garments can be custom-made or prefabricated, and ideally they should be fitted by trained personnel.12,34 Some sleeves start at the wrist and end at the upper arm. Others incorporate the shoulder and fasten with a strap around the upper torso. A compression gauntlet, especially one incorporating the wrist, can be used if the hand is swollen.1 Compression garments should be replaced every 4 to 6 months, or when they begin to lose their elasticity.1,32
Patients may be noncompliant with using compression garments because the garments are unsightly, uncomfortable, difficult to put on and expensive.1 Customized, lightweight and colourful garments may be an option for comfort and wear. Pneumatic compression pumps
There has been only one randomized trial that has evaluated pneumatic compression pumps for the treatment of lymphedema. Dini and colleagues35 assigned 80 women with postmastectomy lymphedema to either intermittent pneumatic compression or no treatment. Women in the treatment group underwent a 2-week cycle of 5 pump sessions per week, each session lasting 2 hours, followed by a 5-week break, and then another 2-week treatment cycle. Although the mean decrease in arm circumference in the treatment group was nearly 4 times that in the control group (1.9 cm v. 0.5 cm), the post-test differences between the 2 groups failed to reach statistical significance (p = 0.084), possibly because of the small sample and the large variability in both the initial arm measurements and the circumferential changes within each group (level II evidence).
The experience with lymphedema pumps has also been reported in a number of level V studies.36,37,38,39,40,41,42 The results have been mixed. These studies were limited by their small samples, mixed populations (arm and leg edema), lack of control groups and lack of outcome measures that assessed symptoms such as pain and heaviness. In one study pneumatic compression produced a reduction in lymphedema volume that was 18% greater than the reduction produced by elastic compression;41 in another study no difference was detected between elastic compression and pneumatic compression.36
No comparative studies have been published to determine the most effective pumping time, pressure levels or kind of pump. There is a suggestion,44 but not unanimous agreement,43 that sequential, multichambered pumps are more effective than monochambered pumps. The former produce a linear pressure wave from distal to proximal portions of the limb that reduces the tendency of fluid to collect in the hand. There are several commercially available pumps, ranging in complexity and cost. Most pumps used by therapists, clinics and consumers are complex and cost several thousand dollars. Pump therapy is contraindicated in the presence of active infection or deep vein thrombosis in the limb. Massage and physical therapies
Complex physical therapy, also called complex decongestive physiotherapy, is a treatment regimen that includes meticulous skin hygiene, manual lymph drainage, bandaging, exercises and support garments. Manual lymph drainage is a massage technique that involves the skin surface only and follows the anatomic lymphatic pathways of the body. A session of manual lymph drainage starts centrally in the neck and trunk to clear out the main lymphatic pathways, thereby facilitating drainage from the arm.45,46,47
A recently published randomized trial involving 42 women with modest stage I or II lymphedema compared standard therapy alone with standard therapy plus manual lymph drainage and training in self-massage (level I evidence).48 Standard therapy included use of a custom-made sleeve-and-glove compression garment worn during the day, instruction in physical exercises, education in skin care, and information and recommendations about lymphedema. Both groups obtained a significant reduction in limb volume, a decrease in discomfort and increased joint mobility over time. However, no significant differences in objective measures of change in arm volume or subjective measures of symptoms related to lymphedema were found between the 2 groups.
In a cohort study involving 35 women, compression bandaging plus manual lymph drainage was compared with compression bandaging alone (level III evidence).49 There was a trend in mean volume reduction and a statistically significant difference between the 2 groups in the percentage reduction in volume in favour of the combined treatment. Symptoms did not differ statistically significantly between the 2 groups. A number of case series have reported on the use of these modalities. Some reported alleviation of lymphedema (level V evidence).50,51,52,53,54,55,56,57 However, interpretation of the results is limited by the methodology of the studies. In another trial, manual lymph drainage plus compression garment use was compared with sequential pneumatic compression plus compression garment use; no difference was detected between the treatment groups (level II evidence).58 In another study, involving 6 months of compression garment use by 120 women, no additional benefit was shown by adding electrically stimulated lymphatic drainage or pneumatic pump therapy (level V evidence).36 Other physical therapy modalities
Other physical therapy modalities, such as laser treatment, electrical stimulation, transcutaneous electrical nerve stimulation (TENS), cryotherapy, microwave therapy and thermal therapy, have been used for lymphedema in breast cancer patients (level V evidence).9,59,60,61,62 However, these modalities need further, rigorous evaluation before recommendations can be made.
A 1993 Italian study compared ultrasonography and pump therapy with a monochambered pump.63 There was no significant reduction in lymphedema with either therapy. In fact, therapeutic ultrasound to areas of potential metastatic disease is contraindicated. A randomized study involving 71 mice showed enhanced tumour growth when high-intensity, continuous ultrasound was applied directly over the tumour.64 Low-intensity, continuous ultrasound and pulsed ultrasound also increased tumour weight and volume, although not as significantly as high-intensity ultrasound.65 Therapeutic ultrasound should not be used over areas of active or potential breast cancer metastases, such as the hips, lumbar area, ribs, chest wall or axillae. Pain management Pain and discomfort associated with lymphedema are common66,67 and should be managed primarily by controlling the lymphedema. Refractory pain can be managed with non-narcotic and narcotic analgesics, with the use of adjuvant analgesics (e.g., tricyclic antidepressants, corticosteroids, anticonvulsants or local anesthetics) when necessary.68 Aggravating conditions, such as infection and recurrence of cancer in the axillary lymph nodes or brachial plexus, should be looked for and treated. Psychosocial issues Because of the psychological morbidity associated with lymphedema, psychosocial issues should be promptly recognized and addressed. Women with lymphedema have been shown to have greater psychiatric morbidity and greater functional disability.69,70,71,72 Surgery, diuretics and benzopyrones
Surgery (e.g., microsurgical lymphovenous anastomoses, creation of a myocutaneous flap with latissimus dorsi muscle, omental transposition, grafting of lymphatic vessels with tubes or threads) has produced disappointing, inconsistent results and should be avoided.2,73,74,75,76,77,78 Diuretics, which have been recommended in the past, may temporarily mobilize water, but the increased interstitial oncotic pressure exerted by the high protein concentration of lymph fluid will cause rapid recurrence of edema.3 The diuretic effect in the rest of the body may cause adverse side effects, such as hypotension, dehydration and electrolyte imbalance.
Benzopyrones were promoted for use in lymphedema because they were felt to stimulate macrophage-induced proteolysis.79,80 Subsequently, a large randomized, placebo-controlled trial of coumarin, a benzopyrone, in 140 women failed to show any benefit (level I evidence).81 These products are no longer recommended. Practical tips
The following suggestions make clinical sense to the authors of this guideline, even though the evidence that supports the suggestions is limited and primarily anecdotal.
Future research The management of lymphedema in breast cancer patients is based primarily on results from case studies, clinical experience and anecdotal information. The natural history and most effective therapies for lymphedema are poorly understood and need further study. Accurate assessment requires agreement on a standardized and reliable system of measurement.88 Randomized controlled trials to answer these questions should be encouraged and funded whenever possible.
Competing interests: None declared.
Contributors: There are 4 principal authors of this guideline article. The Steering Committee for Clinical Practice Guidelines for the Care and Management of Breast Cancer provided scientific and editorial comments, which led to multiple revisions of the manuscript. Dr. Harris is Professor in the School of Rehabilitation Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC; Dr. Hugi is with Providence Health Care, Vancouver, BC; Dr. Olivotto is Clinical Professor in the Division of Radiation Oncology, BC Cancer AgencyVancouver Island Cancer Centre and the University of British Columbia, Victoria, BC; and Dr. Levine is with the Cancer Care Ontario Hamilton Regional Cancer Centre, and the Departments of Medicine and of Clinical Epidemiology and Biostatistics, McMaster University, and is the Buffett Taylor Chair in Breast Cancer Research, McMaster University, Hamilton, Ont. This article has been peer reviewed. Reprint requests to: Dr. Mark Levine, c/o Ms. Humaira Khan, Faculty of Health Sciences, McMaster University Health Sciences Centre, Rm. 2C6, 1200 Main St. W, Hamilton ON L8N 3Z5; fax 905 577-0017 References
Copyright 2001 Canadian Medical Association or its licensors |